<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01596010</url>
  </required_header>
  <id_info>
    <org_study_id>KLI-1915</org_study_id>
    <secondary_id>2007-003350-28</secondary_id>
    <nct_id>NCT01596010</nct_id>
  </id_info>
  <brief_title>Investigation of 2 Different Oral Formulations of Estradiol and Norethisterone in Healthy Women</brief_title>
  <official_title>Single Dose, Double-blind, Two-way Cross-over Bioequivalence Trial With 2 Different Oral Formulations of Estradiol and Norethisterone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this trial is to investigate whether a
      reformulated estradiol/norethisterone acetate (NETA) formulation is bioequivalent to that of
      Kliogest® (estradiol/norethisterone acetate (NETA) in healthy women.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the Curve (0-t)</measure>
    <time_frame>Up to 72 hours after trial product administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax, maximum concentration</measure>
    <time_frame>Up to 72 hours after trial product administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to maximum (tmax)</measure>
    <time_frame>Up to 72 hours after trial product administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve from time zero to infinity</measure>
    <time_frame>Up to 72 hours after trial product administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t½)</measure>
    <time_frame>Up to 72 hours after trial product administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal rate constant</measure>
    <time_frame>Up to 72 hours after trial product administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>Week 8</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Menopause</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>New formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Old formulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2 mg estradiol / 1 mg norethisterone acetate (NETA)</intervention_name>
    <description>A single dose of one tablet under fasting conditions separated by a wash-out period of 2 weeks (+0-2 days) between dosing visits. Administered orally.</description>
    <arm_group_label>New formulation</arm_group_label>
    <arm_group_label>Old formulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal defined as at least 12 months spontaneous amenorrhoea, with serum FSH
             (follicle stimulating hormone) levels at least 40 IU/L and estradiol maximum 25 pg/mL.
             If the date of spontaneous amenorrhoea can not be identified because of previous
             hormone replacement therapy, serum FSH at least 40 IU/L and estradiol maximum 25 pg/mL

          -  Non-smoking

          -  Body Mass Index (BMI) maximum 35.0 kg/m^2

          -  Able to understand, read and speak German fluently

          -  Good state of health evidenced by medical history, physical examination including
             gynecological examination, and results from laboratory examination

          -  Willing to abstain from intake of caffeine containing food and beverages within 48
             hours before drug administration

        Exclusion Criteria:

          -  Known or suspected allergy to trial products or related products

          -  Previous use of oral, transdermal, nasal spray, vaginal preparations and implants
             within 8 weeks prior to the planned first drug administration

          -  Known, suspected or history of breast cancer

          -  Known or suspected estrogen dependent neoplasia e.g. endometrial cancer

          -  Abnormal genital bleeding of unknown aetiology

          -  Known insulin dependent as well as non-insulin dependent diabetes mellitus

          -  Positive test for HIV (human immunodeficiency virus) and/or hepatitis B and C

          -  Systolic blood pressure (BP) above or equal to 160 mm Hg and/or diastolic BP above or
             equal to 100 mm Hg, currently treated or untreated
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Neu-Ulm</city>
        <zip>89231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2012</study_first_submitted>
  <study_first_submitted_qc>May 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2012</study_first_posted>
  <last_update_submitted>March 17, 2015</last_update_submitted>
  <last_update_submitted_qc>March 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Norethindrone</mesh_term>
    <mesh_term>Norethindrone acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

